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The nuclear translocation of insulin-like growth factor receptor type 1 (IGF-1R) has
been documented in a variety of previous studies. The exact mechanism of this
translocation, however, is still poorly understood. Furthermore, the functional role of
IGF-1R in the nucleus shows promise of transcriptional control. This function is par-
ticularly important in cancer cells. Understanding this role may also give insights into
cancer biology and treatment methods. Processes including SUMOylation and
clathrin-mediated endocytosis are necessary for IGF-1R nuclear translocation to
occur. The antiapoptotic qualities of IGF-1R likely contribute to its function in cancer
cells. This review aims to synthesize the work on IGF-1R in order to propose a mech-
anism of translocation. Using this mechanism, new therapeutic targets can be
proposed that hinder the role of IGF-1R in cancer metastasis.
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1 | INTRODUCTION
A growing body of evidence has shown that insulin-like growth factor
(IGF) receptor (IGFR) is translocated to the nucleus in cancer cells.
IGFR is a transmembrane glycoprotein with a structure that consists
of two α subunits and two β subunits.1 The IGF system has been
found to have an important function in the aetiology of breast cancer
and in mammary gland function.2 This review will investigate the work
on the nuclear translocation of IGFR and associated proteins in cancer
cells and the potential for new therapeutic targets. Insulin receptor
(IR) and IGFR type 1 (IGF-1R) evolved from a common ancestral
receptor that functioned in metabolism and organism size regulation.3
The two receptors have since taken on different functions, despite
having similar structures. Although IR is activated by insulin from the
pancreas, IGF-1R uses ligands from the liver. These ligands, IGF-I and
IGF-II, are also produced by tumour cells and stromal fibroblasts. As a
result, IGF-1R specifically, has shown more potential in cancer
research than IR has. Once the ligand binds to IGF-1R, the receptor's
tyrosine kinase domains are activated. Subsequently, binding sites for
docking proteins such as IRS-1 to IRS-4 and collagen domain protein
are phosphorylated. These proteins trigger the phosphatidylinositol-
3-kinase and RAS/RAF/mitogen-activated protein kinase signalling
pathways.3 The 2012 study by Sarfstein et al aimed to investigate the
nuclear translocation of IGF-1R and the related IR in breast cancer
cells, the effect of IGF-IR and IR levels on IGF-1R biosynthesis in
breast cancer cells with oestrogen receptor and without oestrogen
receptor, and the role of IGF-1R as a transcription factor in the con-
text of IGF-1R gene regulation.2 The authors identified an oestrogen
receptor dependent pathway of autoregulation of IGF-IR gene expres-
sion by cellular IGF-IR. This gene regulation was mediated at the tran-
scription level. There are three potential outcomes for internalized
IGF-1R: It can go to the plasma membrane, it can be degraded, or it
can go to the nucleus. A significant amount of IGF-1R has been found
in the nuclei of advanced or malignant prostate cancer cells.4
While investigating the purpose of IGF-1R in cancer cells, the authors
found IGF-1R binding sites at or around the transcription start sites of
certain genes. These genes included JUN and FAM21 and involved
RNA pol II occupancy and histone marks indicating active enhancers
and promoters. This recruitment of IGF-1R to chromatin was
inducible.Current author address: 783 Eagle Avenue, Ann Arbor, MI 48103
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2 | RESULTS AND DISCUSSION
2.1 | InsR and IGF-1R have functional differences
A minireview by Sarfstein and Werner in 2013 compared the form and
function of IR (InsR) and insulin like growth factor 1 receptor (IGF-1R).5
They found considerable homologies between the two with 84% in their
tyrosine kinase domains, 45% to 65% in their ligand binding domains,
and over 50% in their amino acid sequences. They also found that 12 of
the 21 exons in the IGF1R gene are equal in size to homologous exons in
the InsR gene. There is an alternative splicing event on exon 11 of InsR
that creates two isoforms: InsR-A and Ins-B. InsR-A is mainly expressed
in foetal tissues, while InsR-B is mainly expressed in adult liver, muscle,
and adipocytes. IGF-1R however is not found significantly in adipose tis-
sue and not at all in the liver. Instead, it is highly expressed in the brain.
2.2 | SUMOylation is necessary for IGF-1R nuclear
translocation
A number of studies suggest that InsR and IGF-1R are translocated to
the nucleus; however, the mechanism for this is unclear. Both receptors
are found in the perinuclear and nucleolar areas and are modified by
small ubiquitin-like modifier (SUMO). Ligand dependent SUMOylation
is likely a necessity for nuclear translocation to occur. The tyrosine
kinase domain lysine residues, where SUMOylation occurs, are homolo-
gous and conserved across different species. To test the necessary
nature of SUMOylation, these sites underwent mutagenesis, which
prevented nuclear translocation and associated gene activation.6
SUMOylation of IGF-1R has also shown an association with increased
cell proliferation.7 Lin et al used FACS analysis to compare apoptosis
rates of cells with wild type IGF-1R (R-WT) to those with mutated
SUMOylation sites (R-puro and R-TSM). Relative numbers of wild type
IGF-1R-containing cells remained significantly higher than those of the
two mutated groups. They also tested the specific effects of IGF-1R
SUMOylation on cell cycle progression. The researchers brought each
of their cell lines into G1 phase using 36-hour serum starvation. They
found that the most notable impact was the relative increase in S phase
cells and decrease in G1 phase cells for the R-WT group. They also
looked at the expression of different cyclins, CDKs, and CIP/KIP CDK
inhibitors that control the cell cycle phases. The R-WT group uniquely
showed an increase in G1/S cyclin D1 after 10 hours, an increase in S
phase cyclin A after 16 hours, and an increase in G2/M cyclin B1 after
16 and 24 hours. The researchers concluded that IGF-1R SUMOylation
affects cell proliferation by stimulating G1-S progression of the cell
cycle.7 A study by Deng et al in 2011 showed that IGF-1R does not
directly translocate to the nucleus from the endoplasmic reticulum or
Golgi apparatus, as opposed to cell surface.8 Ligand-mediated phos-
phorylation of InsR and IGF1R has also been found to be important for
their nuclear localization. In the 2010 study by Aleksic et al, the authors
used dansylcadaverine and dynamin-1 inhibitor dynasore to inhibit
clathrin-mediated IGF-1R endocytosis.1 Both significantly prevented
nuclear IGF-1R translocation (dansylcadaverine: P < .001; dynamin-1
inhibitor dynasore: P < .05). Considering that clathrin is an important
player in vesicle formation, this data may suggest that IGF-1R translo-
cates to the nucleus via vesicular transport. This study also investigated
whether IGF-1R in the nucleus was cleaved by γ-secretase, for which it
is a known substrate. They concluded that full-length IGF-1R is trans-
located to the nucleus, rather than being cleaved. To test whether
phosphorylation by IGF-1R kinase is necessary for nuclear transport,
Aleksic et al used AZ12253801 as a selective inhibitor of the kinase.1
They found that pretreatment with this inhibitor resulted in a decrease
in phosphorylation and nuclear localization of IGF-1R. IGF-1R was
extracted from melanoma cells, grown with and without serum, using
immunoprecipitation in a study by Sehat et al and then western blotted
using an anti-SUMO-1 antibody.6 Their results showed a 245kD
SUMO-1 signal in the presence of serum, indicating that IGF-1R gets
SUMOylated. The authors identified Lys1025, Lys1100, and Lys1120 as
the three sites of SUMOylation on IGF-1R. When these sites were
mutated, IGF-1R nuclear translocation was inhibited, while membrane-
bound IGF-1R remained the same.6 In serum starved cells that lacked
nuclear IGF-1R, Sehat et al were able to stimulate IGF-1R accumulation
in the nucleus using IGF-1. While IGF-1R lacks a nuclear localization
sequence (NLS) and does not interact with β-importin, it can still
migrate to the nucleus using the NLS of another protein.9 IGF-1 is
known to trigger the nuclear translocation of IR substrate 1 (IRS-1),
which is associated with IGF-1R in signalling pathways and has an NLS.
Sehat et al argue that the potential role of IRS-1 in the transport of
IGF-1R to the nucleus should be investigated in future work.6
2.3 | IGF-1R can bind to double stranded DNA
The ability of nuclear IGF-1R to bind DNA was tested using electropho-
retic mobility shift assays with biotin-labelled, double-stranded, 40-base
pair oligonucleotides.6 Their electrophoretic data showed proteins bind-
ing to a DNA probe, along with a supershift in the presence of an IGF-1R
antibody (Figure 1). This points to an association between the DNA
sequence and IGF-1R, either in complex or by itself. Competitive binding
by unlabelled probes diminished the supershift bands, further supporting
the notion of a physical interaction between IGF-1R and DNA. Further-
more, the receptor bound to only 4 out of 17 tested DNA probes, indi-
cating that this association is sequence specific.6 They tested whether
the bound DNA fragments represent regulatory sequences by sub-
cloning them into the pGL4-minimal promoter vector coding for firefly
luciferase. Cells that were transfected with IGF-1R-containing plasmids
exhibited greater transcription of certain sequences compared with cells
with empty vectors. They concluded that the bound DNA sequences are
enhancer regions and that IGF-1R acts as a transcriptional activator.
2.4 | IGF-1R has transcription regulatory
capabilities
A 2012 study by Warsito et al found that IGF-1R binds LEF-1, which
is a transcription factor that regulates Wnt signalling and activates
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LEF-1/TCF targets.10 They also saw that nuclear IGF-1R binds to the
same site as LEF-1 in the cyclin D1 promoter, which function in cell
cycle progression. While IGF-1R can regulate the Wnt cascade, LEF-
1/TCF can regulate IGF-1R expression in a bidirectional loop
(Figure 2).5 Both InsR and IGF-1R translocate to the nucleus of breast
cancer cells and were found to bind the IGF-1R gene in cells that were
depleted for oestrogen receptors (ERs).2 Nuclear InsR was found to
diminish IGF-1R gene transcription, whereas nuclear IGF-1R was
found to promote its own gene expression.2 A 2011 study by Wang
et al found that many other tyrosine kinase receptors, including ErbB,
fibroblast growth factor, and vascular endothelial growth factor go to
the nucleus and function in transcriptional control.11 This shows that
nuclear translocation and function is a recurring principle in receptor
tyrosine kinases.
2.5 | IGF-1R nuclear activity is prominent in cancer
cells
Many studies on IGF-1R translocation and function in the nucleus
focus on cancer cells. The 2012 study by Sarfstein et al observed the
ER dependency of IGF-1R autoregulation in human breast cancer-
derived MCF7 (ER-positive) and MCF7-derived C4.12.5 (ER-depleted)
cells.2
Inhibition of IGF-1R has been shown to prevent breast cancer
metastasis. A dominant negative form of IGF-1R, called 486stop, was
injected into a mammary fat pad and did not inhibit tumour growth
but did significantly suppress the spread of cancer to the lungs, liver,
lymph nodes, and lymph vessels.12 A study by Schedlich et al tested
IGFR binding proteins (IGFBPs) that are known to help modify the
function of IGF.13 Nuclear translocation of fluorescently labelled
IGFBP-3 and IGFBP-5 was measured in a proportion to rapidly divid-
ing T47D human carcinoma cells. Using this method, IGFBP-5 was
shown to translocate to the nucleus of carcinoma cells. The authors
defined a sequence within IGFBP-3 basic motif that is needed for its
nuclear translocation. The basic carboxyl-terminal domain of IGFBP-3
has a region around amino acids 215 to 232 with notable homology
to bipartite NLS. It also shares homology with the DNA-binding
domains of several transcription factors.13 Wu et al investigated the
role of IGF-1R in the development of prostate cancer and androgen
independent disease.14 They reviewed the published data on the
interactions between IGF-1R and androgen receptor (AR) and suggest
that IGF-1R signalling might affect AR compartmentalization. IGF-1R
may impact the phosphorylation of AR and thus affect its function.
Through its effect on AR activity, IGF-1R can impact prostate cancer
development, which supports the possibility of new therapeutic tar-
gets. The 2018 study by Aleksic et al found further support for cancer
cell nuclear localization by using antibodies for the α and β subunits of
IGF-1R.4 They were able to detect nuclear IGF-1R in highly proliferat-
ing primary renal cancer cells, formalin-fixed tumours, preinvasive
lesions in the breast, and nonmalignant tissues.4 The authors found
both α and β IGF-1R subunits in the nuclei of cancer cells. IGF-1R is
phosphorylated, and then it interacts with chromatin in an IGF
induced manner. The authors used this to argue that IGF-1R is directly
involved in cancer cell transcription regulation. In addition, they
analysed the survival rates of patients with varying degrees of nuclear
IGF-1R. They found that higher levels of nuclear IGF1R significantly
correlated with shorter survival times. Furthermore, Sarfstein and
Werner used the antiapoptotic and pro cell survival capabilities of
IGF1R to explain its high expression levels in tumour cells.5 IGF-1R
activity has been shown to regulate p53 using pathways that can
decrease p53 translation or increase p53 stability.15 This shows how
the receptor may enact its antiapoptotic effects. This would also make
sense with the upregulation of IGF-1R that has been observed in
advanced stage cancer cells.
2.6 | Summary of IGF-1R regulation mechanism
Based on the work examined in this review, the mechanism for IGF-
1R nuclear translocation and transcription regulation in cancer cells is
as follows: IGF-1R undergoes clathrin-mediated endocytosis and is
subsequently SUMOylated on the three 1025, 1100, and 1120 lysine
residues. The protein gets phosphorylated by IGF-1R kinase, interacts
with IRS-1, and travels to the nucleus. The whole receptor is depos-
ited inside, where it binds to specific genes, including its own, and
promotes IGF-1R expression. Nuclear IGF-1R binds to LEF1 transcrip-
tion factor and upregulates cyclin D1 and axin2 levels. SUMOylated
IGF-1R promotes cell proliferation by promoting G1-S cell cycle
F IGURE 1 EMSA (electrophoretic mobility shift) assay for DNA
probes 2 and 5 showing protein binding. Lanes 5 and 7, which lack
the supershift, had unlabelled competitive probes at 200-fold molar
mass. This figure is adapted from Sehat et al, 20106
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progression. Through its disruption of p53 dependent and indepen-
dent cell death, IGF-1R promotes cancer cell survival and metastasis.
2.7 | Future work
Using the mechanism of IGF-1R nuclear translocation and transcrip-
tion regulation, we can identify new targets along the path that can
inhibit the role of IGF-1R in cancer cells. The therapeutic potential of
IGF-1R for cancer has been controversial, but by targeting different
points in the mechanism, a confident treatment method may be devel-
oped that can curb metastasis. Such targets could include preventing
the SUMOylation process needed for nuclear translocation, inhibiting
the clathrin-mediated vesicle formation, and attacking IRS-1 or the
associated IGF-1 proteins. By focusing on the nuclear translocation of
IGF-1R, we can address its cancer-related effects, while still allowing
it to perform its important functions in the cytosol. How exactly
SUMOylated IGF-1R stimulates G1-S progression should be further
investigated. It may specifically upregulate cyclins D1, A, and B1 while
leaving proteins associated with other cell cycle phases unaffected.
The role of IRS-1 should be studied in greater detail. It is also impor-
tant to determine how IGF-1R exactly goes inside the nucleus and the
specific involvement of nuclear pores and vesicles. In addition, a
cinematographic study to observe the exact paths that IGF-1R takes
and which exact areas it is expressed in over the course of this whole
process would be helpful in determining the exact mechanism.
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